01 Growing Cases of COVID-19 Globally COVID-19 is caused by the SARS-CoV-2 virus, which originated in Wuhan, China, in December 2019. The SARS-CoV-2 virus exhibits easy access and communication, directly or indirectly, through human-to-human transmission. The infection rate is massive because of the highly contagious nature of the virus, translating into a higher number of COVID-19 cases worldwide. Further, the high infection rate of this viral infection has resulted in a pandemic, which has emerged as one of the massive humanitarian challenges in recent times. With a steep rise in COVID-19 patients, a vital requirement exists for efficacious vaccines to refuel vaccine innovation. Due to the advantages being offered by the mRNA-based COVID-19 vaccines coupled with the growing cases of COVID-19 worldwide, the demand for these vaccines has massively increased in the last couple of months, which is expected to bolster the growth of the underlying global market in the forthcoming years.
02 Favorable Regulatory Environment With the demand for mRNA-based COVID-19 vaccines getting outpaced due to massively increasing COVID-19 cases worldwide, the regulatory authorities worldwide have loosened restrictions on the regulations of these vaccines. Regulatory authorities such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are offering emergency use authorizations (EMAs) and conditional marketing authorizations (CMAs), respectively, to the company’s manufacturing of mRNA-based COVID-19 vaccines to ensure a constant supply for continuing vaccination strategies.
01 High Price Associated with mRNA-Based COVID-19 Vaccines These vaccines have attracted significant attention from healthcare experts and governments because the mRNA-based COVID-19 vaccines allow the body's molecular process to create its own medicine against the infection, ensuring great efficacy and safety. Although mRNA-based vaccinations are now a crucial component of prosperous economies' effective vaccination programs, underdeveloped nations still face financial difficulties because of the high price of these vaccines. For instance, the estimated average cost of the mRNA-1273 vaccine of Modena, Inc. typically ranges between USD 11 and USD 13 per dose.Similarly, the average cost of BioNTech and Pfizer's BNT162b2 (COMIRNATY) ranges between USD 8 to USD 10 per dose. Since these vaccines are given in two doses per patient, the consolidated cost becomes very high, which is not affordable for citizens in emerging countries. This makes mRNA-based vaccines highly expensive for the governments of emerging economies to purchase in high volumes, creating a lack of accessibility of these highly productive vaccines, further restricting the growth of the underlying global market.
01 Growing Emphasis on Research and Development for Non-COVID-19 Applications The underlying molecular mechanisms associated with the manifestation and progression of cancer, rare diseases, and immunological diseases have been extensively studied to discover novel therapies. The emergence of mRNA-based vaccines and therapies is becoming a promising platform for the development of novel treatments on account of various underlying advantages, which include efficiency in expressing tumor antigens in the antigen-presenting cells (APCs), initiation of an adaptive immune response, and facilitation of APC activation, among others. Extensive research is being conducted on mRNA-based vaccines and therapies for cancer immunotherapy and rare disease treatments. Research institutes and industry players are investigating research on the structural modifications in mRNA and its formulation methods to develop promising drugs based on mRNA.Additionally, companies operating in the mRNA vaccines and therapeutics ecosystem are incorporating industry-academia collaboration to assess and develop novel candidates that could help physicians to treat cancer subtypes and rare, life-threatening diseases. Further, companies focused on developing mRNA-based therapies incorporate synergies with other pharmaceutical companies to develop novel therapies for non-COVID-19 applications. These advancements in the development of mRNA-based therapies for non-COVID-19 applications are expected to offer lucrative opportunities to legacy and emerging companies to expand their portfolio for treating life-threatening disorders, which is anticipated to provide massive growth in the forthcoming years.
April 2026 Moderna expanded its mRNA technology platform by advancing vaccine and therapeutic development programs across infectious diseases, oncology, and rare disease applications. The company continued strengthening research collaborations and manufacturing capabilities to support broader commercialization of mRNA-based medicines.
February 2026 BioNTech expanded its mRNA pipeline through continued development of oncology immunotherapies and infectious disease vaccines. The company focused on advancing clinical programs and strengthening global capabilities for mRNA-based therapeutic manufacturing.
January 2026 Pfizer and BioNTech continued advancing their mRNA vaccine collaboration activities, focusing on next-generation vaccine technologies and broader infectious disease applications. The companies continued research efforts to improve vaccine platforms and address emerging health challenges.
November 2025 CureVac expanded its mRNA technology initiatives through continued development of next-generation mRNA platforms designed to improve stability, delivery efficiency, and therapeutic performance. The company focused on advancing applications beyond traditional vaccines.
September 2025 Arcturus Therapeutics expanded its mRNA and RNA medicines portfolio by advancing vaccine and therapeutic programs using its proprietary delivery technologies. The company continued focusing on improving mRNA delivery systems for infectious disease and rare disease applications.
July 2025 Sanofi expanded its mRNA vaccine capabilities through continued investments in research, manufacturing infrastructure, and partnerships supporting next-generation vaccine development. The company focused on strengthening its position in emerging mRNA-based healthcare solutions.